Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

1 source entries across 1 studies. This list may not include all unresolved or historical entries.

  • Folic acid 400 -1000 μgRegistry intervention

    Linked study entry; product equivalence not established

    View study and source

Success Metrics

Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(100%)

Phase Distribution

Phase 2
1
100%

Phase Distribution

0

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution1 total trials
Phase 2Efficacy & side effects
1(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

1

all time

Status Distribution
Terminated(1)

Detailed Status

Terminated1

Development Timeline

Analytics

Development Status

Total Trials
1
Active
0
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 21 (100.0%)

Trials by Status

terminated1100%

Recent Activity

0 active trials
Showing 1 of 1
terminatedphase_2

KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC

NCT04265534

Clinical Trials (1)

Showing 1 of 1 trials
NCT04265534Phase 2

KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC

Terminated

All 1 trials loaded

Drug Details

Intervention Type
Dietary supplement
Total Trials
1